Holen Sie sich die Stockscreener-App
0.69
20.42%
0.117
Handel nachbörslich:
.69
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
VistaGen Therapeutics (VTGN) Q4 2026 earnings summary - Quartr
VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings - Quiver Quantitative
vtgn-20260331 - SEC.gov
VTGN: Net loss increased to $69.7M as R&D spending rose, with cash reserves at $45.4M and going concern risk - TradingView
Vistagen Reports FY2026 Net Loss $69.7M; Cash and Marketable Securities $45.4M - TradingView
VTGN: Advanced clinical milestones and maintained cash runway despite increased net loss - TradingView
Vistagen (NASDAQ: VTGN) advances fasedienol trials as FY 2026 loss deepens - Stock Titan
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - Business Wire
Generalized Anxiety Disorder Market: Growth Momentum Across 7MM to 2036 – DelveInsight | VistaGen Therapeutics, Fabre-Kramer Pharm, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Lab - Barchart.com
VTGN Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Edges HigherGuidance vs Actual - newsline.com
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Vistagen Therapeutics (VTGN) Edges Higher Amid Cautious TradingRVOL Breakout - newsline.com
Vistagen (VTGN) Achieves Key Milestone in Social Anxiety Disorder Treatment - GuruFocus
Vistagen achieves ICH E1 safety exposure milestones for fasedienol; >1,500 subjects exposed - TradingView
Vistagen (VTGN) reaches ICH safety exposure goal in Phase 3 fasedienol program - Stock Titan
Vistagen meets ICH E1 safety exposure targets for fasedienol By Investing.com - Investing.com Australia
Nasal spray for social anxiety clears key safety bar in 1,500 people - Stock Titan
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm - GuruFocus
Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching - Bez Kabli
VTGN Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineEPS Revision Trend - The Legal Advocate
Vistagen (VTGN) Prepares for Jefferies Healthcare Conference Ami - GuruFocus
Vistagen (VTGN) Prepares for Jefferies Healthcare Conference Amid Key Trial Updates - GuruFocus
Investor meetings as Vistagen joins Jefferies 2026 healthcare event in NYC - Stock Titan
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference - Yahoo Finance
Vistagen Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Vistagen Therapeutics (VTGN) Holds Near Support After Minor DeclineBullish Sentiment - The Legal Advocate
Vistagen Therapeutics (VTGN) Shows Modest Gain Amid Tight Trading RangeWave Equality - The Legal Advocate
Vistagen Therapeutics (VTGN) Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesExpert Market Insights - Newser
VTGN Stock Price, Quote & Chart | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
VTGN Q1 2026 Earnings: Narrower-than-Expected Loss as Vistagen Advances Pipeline, Stock Edges LowerSubscription Growth Report - The Legal Advocate
VistaGen Appoints New Chief Medical Officer to Advance Pipeline - The Globe and Mail
VTGN: Fasedienol nears pivotal phase III data in SAD, with pipeline progress and cash runway into 2027 - TradingView
Vistagen Therapeutics (VTGN) Stock: Up +0.98%, Key Resistance at $0.67 2026-05-20Bull Flag - The Legal Advocate
[Form 4] Vistagen Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 3] Vistagen Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vistagen (VTGN) hires Angel S. Angelov, MD, MBA as Chief Medical Officer with option grant - Stock Titan
VTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class ActionVTGN - TMX Newsfile
Vistagen appoints Angel S. Angelov as chief medical officer - marketscreener.com
Vistagen appoints Angel Angelov as chief medical officer By Investing.com - Investing.com Australia
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer - Yahoo Finance
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
[SCHEDULE 13G/A] Vistagen Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
All News about Vistagen Therapeutics, Inc.Common Stock - The Chronicle-Journal
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Inside Vistagen: CEO joins RBC healthcare fireside chat on May 20 - Stock Titan
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - marketscreener.com
Vistagen Therapeutics, Inc.Common Stock (NQ: VTGN - FinancialContent
Vistagen Reports Positive 12-Month Data for Fasedienol Nasal Spray in Social Anxiety Disorder Phase 3 Trial - Minichart
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Vistagen (VTGN) Reports Positive Data from Fasedienol Study for Social Anxiety - GuruFocus
VistaGen Reports Positive Long-Term Data for Fasedienol - TipRanks
Vistagen announces preliminary positive data in ongoing open-label extension portion of PALISADE-3 phase 3 study of fasedienol for the acute treatment of social anxiety disorder - marketscreener.com
Vistagen announces positive OLE safety and 4-month efficacy signals for fasedienol in social anxiety - TradingView
Vistagen (NASDAQ: VTGN) reports positive PALISADE-3 OLE results - Stock Titan
Vistagen reports preliminary data from social anxiety trial By Investing.com - Investing.com Canada
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):